Cargando…

Type I interferonopathies in pediatric rheumatology

Defective regulation of type I interferon response is associated with severe inflammatory phenotypes and autoimmunity. Type I interferonopathies are a clinically heterogenic group of Mendelian diseases with a constitutive activation of this pathway that might present as atypical, severe, early onset...

Descripción completa

Detalles Bibliográficos
Autores principales:	Volpi, Stefano, Picco, Paolo, Caorsi, Roberta, Candotti, Fabio, Gattorno, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893274/ https://www.ncbi.nlm.nih.gov/pubmed/27260006 http://dx.doi.org/10.1186/s12969-016-0094-4

Ejemplares similares

Identification of type I interferonopathies using blood interferon signature: the experience of a pediatric rheumatology center
por: Volpi, S, et al.
Publicado: (2015)

Type I Interferonopathies in Childhood
por: Haşlak, Fatih, et al.
Publicado: (2023)

The type I interferonopathies: 10 years on
por: Crow, Yanick J., et al.
Publicado: (2021)

Type I Interferonopathies in Children: An Overview
por: d'Angelo, Debora M., et al.
Publicado: (2021)

Type I interferon–mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview
por: Rodero, Mathieu P., et al.
Publicado: (2016)

Myasthenia Gravis: An Acquired Interferonopathy?
por: Payet, Cloé A., et al.
Publicado: (2022)

Covid-19–Associated Myopathy Caused by Type I Interferonopathy
por: Manzano, Giovanna S., et al.
Publicado: (2020)

Syndrome of Undifferentiated Recurrent Fever (SURF): An Emerging Group of Autoinflammatory Recurrent Fevers
por: Papa, Riccardo, et al.
Publicado: (2021)

Clinical spectrum and currently available treatment of type I interferonopathy Aicardi–Goutières syndrome
por: Dell’Isola, Giovanni Battista, et al.
Publicado: (2023)

Case Report: Susceptibility to viral infections and secondary hemophagocytic lymphohistiocytosis responsive to intravenous immunoglobulin as primary manifestations of adenosine deaminase 2 deficiency
por: Drago, Enrico, et al.
Publicado: (2022)

Fine-tuning of type I IFN-signaling in microglia — implications for homeostasis, CNS autoimmunity and interferonopathies
por: Goldmann, Tobias, et al.
Publicado: (2016)

A child with a novel ACAN missense variant mimicking a septic arthritis
por: Florio, Angelo, et al.
Publicado: (2019)

Lung involvement in monogenic interferonopathies
por: Cazzato, Salvatore, et al.
Publicado: (2020)

Human RELA dominant-negative mutations underlie type I interferonopathy with autoinflammation and autoimmunity
por: Moriya, Kunihiko, et al.
Publicado: (2023)

Efficacy of Baricitinib in the Treatment of Chilblains Associated With Aicardi‐Goutières Syndrome, a Type I Interferonopathy
por: Meesilpavikkai, Kornvalee, et al.
Publicado: (2019)

Type I Interferonopathy due to a Homozygous Loss-of-Inhibitory Function Mutation in STAT2
por: Zhu, Gaofeng, et al.
Publicado: (2023)

An Update on Familial Mediterranean Fever
por: Lancieri, Maddalena, et al.
Publicado: (2023)

Human Disease Phenotypes Associated with Loss and Gain of Function Mutations in STAT2: Viral Susceptibility and Type I Interferonopathy
por: Duncan, Christopher James Arthur, et al.
Publicado: (2021)

Monogenic interferonopathy presenting as CMV infection in infancy
por: Schütz, C, et al.
Publicado: (2015)

Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS)
por: Kanazawa, Nobuo, et al.
Publicado: (2023)

Chronic active EBV infection mimicking periodic fever syndromes: a new challenge for the paediatrician
por: Caorsi, Roberta, et al.
Publicado: (2014)

Monogenic polyarteritis: the lesson of ADA2 deficiency
por: Caorsi, Roberta, et al.
Publicado: (2016)

Type 1 Diabetes and Type 1 Interferonopathies: Localization of a Type 1 Common Thread of Virus Infection in the Pancreas
por: Jean-Baptiste, Virginie S.E., et al.
Publicado: (2017)

Enlarging the clinical spectrum of SAVI syndrome
por: Caorsi, R, et al.
Publicado: (2015)

Long-term efficacy of etanercept in ADA2 deficiency
por: Caorsi, Roberta, et al.
Publicado: (2014)

Mosaic tetrasomy 9p: a mendelian interferonopathy associated with pediatric-onset overlap myositis
por: Frémond, M-L, et al.
Publicado: (2015)

Chronic Infantile Neurological Cutaneous and Articular (CINCA) syndrome: a review
por: Finetti, Martina, et al.
Publicado: (2016)

CD70 Deficiency due to a Novel Mutation in a Patient with Severe Chronic EBV Infection Presenting As a Periodic Fever
por: Caorsi, Roberta, et al.
Publicado: (2018)

Homozygous STAT2 gain-of-function mutation by loss of USP18 activity in a patient with type I interferonopathy
por: Gruber, Conor, et al.
Publicado: (2020)

Type I interferonopathies with novel compound heterozygous TREX1 mutations in two siblings with different symptoms responded to tofacitinib
por: Zhang, Shiyu, et al.
Publicado: (2021)

Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China
por: Li, Wendao, et al.
Publicado: (2022)

JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
por: Sanchez, Gina A. Montealegre, et al.
Publicado: (2018)

Adenosine Deaminase 2 Deficiency (DADA2): A Crosstalk Between Innate and Adaptive Immunity
por: Signa, Sara, et al.
Publicado: (2022)

Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome
por: Volpi, Stefano, et al.
Publicado: (2019)

Policy challenges for the pediatric rheumatology workforce: Part I. Education and economics
por: Henrickson, Michael
Publicado: (2011)

Musculoskeletal ultrasound in pediatric rheumatology
por: Tok, Fatih, et al.
Publicado: (2011)

Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome
por: Meuwissen, Marije E.C., et al.
Publicado: (2016)

ZBP1 contributes to interferonopathies caused by impaired ADAR1 function
por: Fang, Xiuwu, et al.
Publicado: (2022)

Multidimensional definition of the interferonopathy of Down syndrome and its response to JAK inhibition
por: Galbraith, Matthew D., et al.
Publicado: (2023)

Long-term follow-up of systemic onset juvenile idiopathic arthritis patients treated with Anakinra
por: Gattorno, Marco, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_e2uvfi6vvtpb9a06skldm980a4